Brief: BeyondSpring Presents Phase 1 Data On Anti-Cancer Effect Of Plinabulin In Combination With Checkpoint Inhibitors In SCLC At The American Society Of Clinical Oncology Annual Meeting
BeyondSpring Inc reports results for the quarter ended in December - Earnings Summary
Brief: Beyondspring Announces Submission Of New Drug Application To U.S. FDA And China NMPA For Plinabulin And G-CSF Combination
U.S. RESEARCH ROUNDUP- Aprea Therapeutics, Beyondspring, Cognizant Technology
Brief: Beyondspring Appoints Jeffrey Vacirca To Its Board Of Directors
Brief: Beyondspring Says Well On Track To Submit Nda For Plinabulin Cin Program In Q1 2021
Brief: Beyondspring Inc Announces Pricing Of Its Public Offering Of 7.5 Million Ordinary Shares At A Public Offering Price Of $10.00 Per Share
Brief: Beyondspring Announces Proposed Public Offering Of Ordinary Shares
Brief: BeyondSpring Reports Q3 Loss Per Share $0.48
BeyondSpring: Up as therapy for cancer patients meets main study goal
Brief: Beyondspring Announces Positive Topline Results From Its Protective-2 Phase 3 Registrational Trial Of Plinabulin In Combination With Pegfilgrastim For Prevention Of Chemotherapy-Induced Neutropenia
BeyondSpring: Rises on drug development pact with Eli Lilly
Brief: Beyondspring Subsidiary, Seed Therapeutics, Announces Research Collaboration And License Agreement With Lilly
Brief: Beyondspring Files For Shelf Of Up To 10 Mln Ordinary Shares - SEC Filing
Brief: BeyondSpring Forms Partnership Advisory Committee
Brief: Jama Oncology Highlights Plinabulin's Efficacy In Preventing Chemotherapy-Induced Neutropenia As A Monotherapy
Brief: BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
Brief: Beyondspring - Expect To File NDA For Cin To U.S. FDA By End Of Year
Brief: Xiangmin Cui Reports 11.3% Stake In Beyondspring